Meridian Health Labs: What Is Nuevo Worth, and What WACC Proves It
Meridian Health Labs (MHL) is bidding for 100% of Nuevo Diagnostics. Nuevo's forecast free cash flow to the firm for the coming year is ₹92 crore, assumed to grow at 3% in perpetuity thereafter. Nuevo's target capital structure is 31% debt and 69% equity at market values, and its pre-tax cost of debt is 9.5%. The only listed comparable has an equity beta of 0.95 and operates at a debt/equity ratio of 0.25 at market values. The risk-free rate is 7.1%, the market risk premium 6.0% and the tax rate 25.17%. MHL's own WACC is 9.6%, and its treasurer argues this rate should be used "because MHL will fund the acquisition and MHL's shareholders bear the risk". Management's synergy estimate has a present value of ₹210 crore before ₹95 crore of integration costs. Nuevo carries ₹310 crore of net debt and has no other claims. MHL's board has tabled an offer of ₹1,150 crore for the equity and wants the deal signed within four weeks. One director has noted, without analysis, that "almost all of the value seems to sit in the terminal year".
1. Recompute Nuevo's WACC from the data given, showing the unlevering and relevering of the comparable's beta. Explain to the treasurer why Meridian's 9.6% WACC is the wrong discount rate here.
Read the worked answer
Step 1 - Unlever the comparable's beta using its own D/E of 0.25 and (1 − t) = 0.7483: βu = 0.95 ÷ [1 + 0.7483 × 0.25] = 0.95 ÷ 1.1871 = 0.80
Step 2 - Relever at Nuevo's D/E. Nuevo's 31/69 weights imply D/E = 0.31 ÷ 0.69 = 0.449: βL = 0.80 × [1 + 0.7483 × 0.449] = 0.80 × 1.336 = 1.07
Step 3 - Cost of equity (CAPM): Ke = 7.1% + 1.07 × 6.0% = 13.5%
Step 4 - After-tax cost of debt: 9.5% × 0.7483 = 7.11%
Step 5 - WACC: (0.69 × 13.5%) + (0.31 × 7.11%) = 9.32% + 2.20% = 11.5%
Why 9.6% is wrong. A discount rate must price the risk of the cash flows being discounted, not the risk of the payer. MHL's 9.6% reflects MHL's business mix and its own leverage; Nuevo's diagnostics cash flows carry different operating risk (captured by the relevered asset beta) and a different capital structure. Using 9.6% would value Nuevo as though it were a division of MHL and would mathematically justify overpaying. How the deal is financed - cash, debt or shares - is a financing decision and, under Modigliani–Miller with the interest tax shield valued separately, does not change the appropriate rate for the asset. The only legitimate adjustment would be a separately computed synergy value discounted at the acquirer's rate, kept outside the target valuation.
2. Value Nuevo's equity and determine the maximum price Meridian can justify paying given the synergy and integration estimates. What is your recommendation on the ₹1,150 crore offer?
Read the worked answer
Standalone enterprise value (perpetuity growth): EV = 92 ÷ (0.1153 − 0.03) = 92 ÷ 0.0853 = ₹1,079 crore
Standalone equity value = 1,079 − 310 net debt = ₹769 crore
Value of control to MHL = 769 + (210 − 95) = 769 + 115 = ₹884 crore
This ₹884 crore is the walk-away price: it is the point at which every rupee of synergy has been handed to Nuevo's sellers.
Assessment of the ₹1,150 crore offer:
- Premium over standalone equity: 1,150 − 769 = ₹381 crore
- Net synergy available: ₹115 crore
- Value transferred from MHL shareholders to Nuevo's sellers: 381 − 115 = ₹266 crore destroyed
The offer fails. Even at the standalone value plus the full gross synergy of ₹210 crore (ignoring integration cost), the ceiling is ₹979 crore - still ₹171 crore below the bid.
Sanity check on the discount-rate error: at the treasurer's 9.6%, EV = 92 ÷ 0.066 = ₹1,394 crore and equity = ₹1,084 crore, making the maximum price ₹1,199 crore and the ₹1,150 crore offer look attractive. The choice of discount rate alone moves the walk-away price by over ₹300 crore. That is why the WACC must be agreed and minuted before price negotiation begins.
Recommendation: withdraw the ₹1,150 crore offer; table a conditional bid at no more than ₹880 crore (leaving a margin for synergy shortfall), with a stated walk-away and no re-opening on "strategic" grounds unless the synergy estimate is re-based on evidence.
3. The terminal value is a large share of the enterprise value. Quantify that share and identify the sensitivities the board should require before authorising a binding bid.
Read the worked answer
Quantify the terminal dependence. FCF in year 2 = 92 × 1.03 = ₹94.76 crore Terminal value at the end of year 1 = 94.76 ÷ (0.1153 − 0.03) = ₹1,111 crore Present value of TV = 1,111 ÷ 1.1153 = ₹996 crore Share of EV = 996 ÷ 1,079 = 92%
Only about ₹83 crore of the ₹1,079 crore enterprise value comes from the explicit forecast period. The valuation is, in substance, a bet on the perpetual growth rate.
Sensitivities the board should demand (single-variable, then combined):
| Variable | Value | EV (₹ crore) |
|---|---|---|
| g = 2% | 92 ÷ 0.0953 | 965 |
| g = 3% (base) | 92 ÷ 0.0853 | 1,079 |
| g = 4% | 92 ÷ 0.0753 | 1,222 |
| WACC = 11.0% | 92 ÷ 0.0800 | 1,150 |
| WACC = 12.0% | 92 ÷ 0.0900 | 1,022 |
A 50 basis point move in WACC or a 1 point move in g shifts value by ₹65–140 crore - the same order of magnitude as the entire net synergy. The board is being asked to pay a price that is smaller than the model error.
Tests before a binding bid:
- Replace the constant-growth assumption with an explicit 5–7 year forecast and a fade to steady state; show the year in which growth actually settles at 3%.
- Widen the beta estimate - one comparable is not a peer group; request a range (e.g. 0.70–0.90 unlevered) and present a valuation range, not a point.
- Stress a downside case where g = 2% and WACC = 12.5%, and confirm MHL's covenants still hold at that price.
- Value synergies independently (cost, revenue, tax) and phase them; if they depend on staff retention or system migration, apply an explicit probability.
- Fix the consideration structure - an earn-out or deferred tranche tied to Nuevo's FY27–FY28 EBITDA would transfer terminal-value risk back to the sellers, which a cash bid cannot do.